AMERICAN CONSOLIDATED LABORATORIES INC
10KSB/A, 1996-08-05
OPHTHALMIC GOODS
Previous: IDS SHURGARD INCOME GROWTH PARTNERS LP, SC 14D1/A, 1996-08-05
Next: AMERICAN CONSOLIDATED LABORATORIES INC, 10QSB, 1996-08-05




                                 FORM 10 - KSB-A

                       SECURITIES AND EXCHANGE COMMISSION
                            WASHINGTON, D.C. 20549

              ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Commission file number 000-18448  For the fiscal year ended December 31, 1995


                    AMERICAN CONSOLIDATED LABORATORIES, INC.
        _______________________________________________________________
             (Exact name of registrant as specified in its charter )

        FLORIDA                                        59-2624130
(State or other jurisdiction of                   ( I.R.S. Employer
incorporation or organization)                    Identification No.)

             1640 NORTH MARKET DRIVE, RALEIGH, NORTH CAROLINA 27609
               (Address of principal executive offices) (Zip code)

                                 (919) 872- 0744
               Registrant's telephone number, including area code

                                                 Name of each Exchange
       Title of Each Class                        on Which Registered
                 None                                    None

                        SECURITIES REGISTERED PURSUANT TO
                             SECTION 12 (g) THE ACT:

                          Common Stock, $0.05 Par Value
                                 Title of class

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes (X) NO

Registrant's revenues for the year ended December 31, 1995 were $9,003,229.  The
aggregate   market  value  of  the  Common  Stock  of  the  Registrant  held  by
non-affiliates  as of  February  28,  1996 was  $374,222.  The  number of shares
outstanding  of  Common  Stock  of the  registrant  as of  February28,  1996 was
4,436,927.

                       DOCUMENTS INCORPORATED BY REFERENCE

Proxy Statement for Annual Meeting of Shareholders. (The Company intends to file
with the  Commission a definitive  proxy  statement  pursuant to Regulation  14A
prior to April 30, 1996.)




<TABLE> <S> <C>



<ARTICLE> 5
<CIK> 0000823187
<NAME> ACL
<CURRENCY> US DOLLARS
       
<S>                         <C>               <C>                 <C>              <C>
<PERIOD-TYPE>               3-MOS             6-MOS               9-MOS            12-MOS
<FISCAL-YEAR-END>           DEC-31-1995       DEC-31-1995         DEC-31-1995      DEC-31-1995
<PERIOD-START>              JAN-01-1995       APR-01-1995         JUL-01-1995      OCT-01-1995
<PERIOD-END>                MAR-31-1995       JUN-30-1995         SEP-30-1995      DEC-30-1995
<EXCHANGE-RATE>                       1                 1                   1                1
<CASH>                          138,795            96,209              98,026           37,772
<SECURITIES>                          0                 0                   0                0
<RECEIVABLES>                 1,154,102         1,423,733           1,416,656          635,032
<ALLOWANCES>                     87,000            82,100              78,100          216,000
<INVENTORY>                     848,016         1,054,910             858,769        1,094,743
<CURRENT-ASSETS>              2,260,109         2,754,686           2,442,863        1,772,728
<PP&E>                        1,717,045         1,778,392           1,895,292        1,750,324
<DEPRECIATION>                1,102,210         1,139,221           1,175,522        1,128,838
<TOTAL-ASSETS>                4,377,808         4,983,758           4,664,367        3,841,558
<CURRENT-LIABILITIES>         2,245,963         2,163,243           1,944,878        2,662,955
<BONDS>                               0                 0                   0                0
                 0                 0                   0                0
                           0                 0                   0                0
<COMMON>                        196,153           208,409             214,097          221,847
<OTHER-SE>                            0                 0                   0        (225,000)
<TOTAL-LIABILITY-AND-EQUITY>  4,377,808         1,934,561           4,664,367        3,841,558
<SALES>                       2,188,528         2,641,113           2,523,295        1,650,293
<TOTAL-REVENUES>              2,188,528         2,641,113           2,523,295        1,650,293
<CGS>                         1,442,277         1,748,661           1,545,335        1,503,802
<TOTAL-COSTS>                   799,903         1,002,360           1,224,293        1,511,257
<OTHER-EXPENSES>                      0                 0                   0                0
<LOSS-PROVISION>                      0            (4,900)             (4,000)         137,900
<INTEREST-EXPENSE>               35,597            37,358              36,876          104,705
<INCOME-PRETAX>                 (73,913)         (129,448)           (282,260)     (1,608,825)
<INCOME-TAX>                          0                 0                   0                0
<INCOME-CONTINUING>             (73,913)         (129,448)           (282,260)     (1,608,825)
<DISCONTINUED>                        0                 0                   0                0
<EXTRAORDINARY>                       0                 0                   0                0
<CHANGES>                             0                 0                   0                0
<NET-INCOME>                    (73,913)         (129,448)           (282,260)     (1,608,825)
<EPS-PRIMARY>                     (0.02)            (0.03)              (0.07)          (0.51)
<EPS-DILUTED>                         0                 0                   0                0
        



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission